Actively Recruiting
Phase 12 Study of Sequential CD146 and HER2 Targeted CAR-T Cell Therapy for Advanced Sarcomas
Led by Essen Biotech · Updated on 2025-07-15
60
Participants Needed
1
Research Sites
54 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new dual CAR-T cell therapy targeting CD146 and HER2 in patients with advanced sarcomas, including soft tissue and bone sarcomas that have come back or do not respond to standard treatments. This open-label, non-randomized Phase 12 trial aims to assess safety, determine appropriate dosing, and explore preliminary effectiveness in reducing tumor size and improving survival. The study is sponsored by Essen Biotech and includes children and adults with measurable disease who have had prior systemic therapy. Participants will first receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide to prepare their bodies for CAR-T therapy. Then, they will be given sequential infusions of CD146-targeted and HER2-targeted CAR-T cells intravenously, initially on day 0, with possible additional doses for those responding well without severe side effects. The trial includes a Phase 1 dose-escalation portion to find the recommended dose and a Phase 2 expansion to further evaluate safety and early efficacy. Throughout the study, participants will be closely monitored for side effects such as cytokine release syndrome and neurotoxicity, with follow-up lasting up to 36 months to observe long-term safety and treatment response. Assessments include physical exams, lab tests, imaging scans every 8 to 12 weeks, and analysis of immune responses. Researchers will measure dose-limiting toxicities, tumor response rates, progression-free and overall survival, aiming to understand how well dual CAR-T therapy works and its safety profile in advanced sarcoma patients.
CONDITIONS
Brief Title
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Research Team
R
Rhoda M Smith, Phd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here